Practice guidelines for the management of community-acquired pneumonia in adults

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 347-382

  Bartlett, John G ^a   Dowell, Scott F ^b   Mandell, Lionel A ^f   File, Thomas M ^c   Musher, Daniel M ^d   Fine, Michael J ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NORTHEAST OHIO MEDICAL UNIVERSITY   (United States)

^d MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

^f MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAMASE INHIBITOR; CEFOTAXIME; CEFPODOXIME; CEFPROZIL; CEFUROXIME; CHLORAMPHENICOL DERIVATIVE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; QUINUPRISTIN; TROVAFLOXACIN; UNINDEXED DRUG; VANCOMYCIN;

ADULT; ALGORITHM; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; HUMAN; LOBAR PNEUMONIA; MORTALITY; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM;

ADULT; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; MIDDLE AGED; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; UNITED STATES;

EID: 0034458012     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313954     Document Type: Review

References (218)

1. Guidelines for the initial empiric therapy of community-acquired pneumonia: Proceedings of an American Thoracic Society Consensus Conference
2. Guidelines for the management of community-acquired pneumonia in adults admitted to hospital
3. Antimicrobial treatment of community-acquired pneumonia in adults: A conference report
4. Community-acquired pneumonia in adults: Guidelines for management. Infectious Diseases Society of America
5. Purpose of quality standards for infectious diseases
6. Trends in infectious diseases mortality in the United States
7. Premature deaths, monthly mortality monthly physician contacts: United States
8. Incidence of community-acquired pneumonia requiring hospitalizations: Results of a population-based active surveillance study in Ohio
9. Prognosis and outcomes of patients with community-acquired pneumonia
10. A prediction rule to identify low-risk patients with community-acquired pneumonia
11. The cost of treating patients with community-acquired pneumonia
12. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia
13. Risk factors for pneumonia in the elderly
14. The impact of alcohol-related diagnoses on pneumonia outcomes
15. Predicting hospital-associated mortality for medical patients
16. Changes in sickness at admission following the introduction of the prospective payment systems
17. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
18. Comparison of a disease-specific and a generic severity of illness measure for patients with community-acquired pneumonia
19. Hospitalization decision in patients with community-acquired pneumonia: A prospective cohort study
20. Predictors of mortality in the immunocompromised patient with pulmonary infiltrates
21. Positive response to any of seven intradermal antigens predicts favorable outcome in patients hospitalized with community-acquired pneumonia
22. Clinical prognostic indices of fatality in elderly patients admitted to hospital with acute pneumonia
23. Pulmonary complications of diabetes mellitus: Pneumonia
24. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization
25. Prognosis of patients hospitalized with community-acquired pneumonia
26. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors and outcome
27. Predicting death in patients hospitalized for community-acquired pneumonia
28. Do pulmonary radiographic findings at presentation predict mortality in patients with community-acquired pneumonia?
29. The hospital admission decision for patients with community-acquired pneumonia
30. Variation in hospital admissions among small areas: A comparison of Maine and Michigan
31. Are hospital services rationed in New Hampshire or overutilized in Boston?
32. Predicting the need for hospitalization of ambulatory patients with pneumonia
33. Severe community-acquired pneumonia: Epidemiology and prognostic factors
34. Appropriateness of hospitalization of patients with community-acquired pneumonia
35. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: An interventional trial
36. A controlled trial of a critical pathway for treatment of community-acquired pneumonia
37. Preference for home vs. hospital care among low-risk patients with community-acquired pneumonia
38. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
39. Community-acquired pneumonia: Impact of immune status
40. Clinical diagnosis of legionnaires' disease (LD) using a multivariate model
41. Clinical features that differentiate hantavirus pulmonary syndrome from three other acute respiratory illnesses
42. Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus
43. Pneumococcal disease during HIV infection: Epidemiologic, clinical and immunologic perspectives
44. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: Incidence, etiologies, and clinical aspects
45. Surveillance for legionnaires' disease: Risk factors for morbidity and mortality
46. Mycoplasma infections of man
47. Infections due to species of Mycoplasma and Ureaplasma: An update
48. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta
49. Hantaviruses and hantavirus pulmonary syndrome
50. Antibiotic prescribing for adults with colds, upper respiratory tract infections and bronchitis by ambulatory care physicians
51. Decreasing antibiotic use in ambulatory practice: Impact of a multidimensional intervention on the treatment of uncomplicated acute bronchitis in adults
52. Diagnosing pneumonia by physical examination: Relevant or relic?
53. HIV infection among patients in US acute-care hospitals
54. High-resolution computed tomography for the diagnosis of community-acquired pneumonia
55. Clinical prediction rule for pulmonary infiltrates
56. Prediction of pneumonia in outpatients with acute cough: A statistical approach
57. Pneumonia due to Legionella pneumophila and pneumococcal pneumonia: Similarities and differences on presentation
58. Community-acquired pneumonia: The future of the microbiology laboratory: Focused diagnosis or syndromic management?
59. Early recognition of Streptococcus pneumoniae in patients with community-acquired pneumonia
60. Initial investigation and treatment of the patient with severe community-acquired pneumonia
61. Diagnosis of bacterial infection of the lung
62. Community-acquired pneumonia
63. The value of the sputum gram's stain in community-acquired pneumonia
64. Management of pneumonia in the prospective payment era: A need for more clinician and support service interaction
65. Relevance of nucleic acid amplification techniques for diagnosis of respiratory tract infections in the clinical laboratory
66. Influence of blood culture results on antibiotic choice in treatment of bacteremia
67. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiologic investigations
68. The value of routine microbial investigation in community-acquired pneumonia
69. The value of routine microbial investigation in community-acquired pneumonia
70. Diagnostic fiberoptic bronchoscopy and protected brush culture in patients with community-acquired pneumonia
71. A criterion based audit of community-acquired pneumonia
72. Severe community-acquired pneumonia: Etiology, prognosis, and treatment
73. A new diagnostic approach to the patient with severe pneumonia
74. Sputum gram stain assessment in community-acquired bacteremic pneumonia
75. Severe community-acquired pneumonia: Epidemiology and prognostic factors
76. Processes and outcomes of care for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Reasearch Team (PORT) Cohort Study
77. Etiological diagnosis of bacterial pneumonia by gram stain and quantitative culture of expectorates
78. Importance of the sputum gram stain in community-acquired pneumonia
79. Diagnostic significance of the sputum gram's stain in pneumonia
80. Microscopic and bacteriologic analysis of expectorated sputum
81. Microscopic and bacteriological comparison of paired sputa and transtracheal aspirates
82. Transportation delay and the microbiological quality of clinical specimens
83. Survival of Streptococcus pneumoniae in sputum from patients with pneumonia
84. Evaluation of housestaff physicians' preparation and interpretation of sputum gram stains for community-acquired pneumonia
85. The nonvalue of sputum culture in the diagnosis of pneumococcal pneumonia
86. Nonvalue of sputum culture in the management of lower respiratory tract infections
87. Diagnostic accuracy of transtracheal aspiration bacteriologic studies
88. Invasive diagnostic techniques in pulmonary infections
89. Superinfections of the lung: An evaluation by serial transtracheal aspirations
90. Etiologic diagnosis of lower respiratory tract infections
91. The reliability of sputum typing and its relation to serum therapy
92. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: Comparison between bronchoalveolar lavage and telescoping-plugged catheter cultures
93. Comparison of PCR, culture, and serological tests for diagnosis of Mycoplasma pneumoniae respiratory tract infection in children
94. Diagnosis of Mycoplasma pneumoniae pneumonia in children
95. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen
96. Evidence that Chlamydiapneumoniae causes pneumonia and bronchitis
97. Legionnaires' disease
98. Reevaluation of the definition of legionnaires' disease: Use of the urinary antigen assay
99. Rapid diagnostic tests for influenza
100. Should fiberoptic bronchoscopy aspirates be cultured?
101. Diagnosis of bacterial pulmonary infections during quantitative protected catheter cultures obtained during bronchoscopy
102. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture
103. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia
104. Fiberoptic bronchoscopy
105. Prevention control of influenza: Recommendations of the Advisory Committee on Immunization (ACIP)
106. Antimicrobial resistance in Streptococcus pneumoniae: An overview
107. Antimicrobial resistant of Streptococcus pneumoniae in the United States, 1979-1987. The Pneumococcal Surveillance Working Group
108. Antimicrobial resistance in Streptococcus pneumoniae: An overview
109. Surveillance of resistance among respiratory tract pathogens in the United States, 1997-1998
110. Management of infections due to antibiotic-resistant Streptococcus pneumoniae
111. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY antimicrobial surveillance program
112. Bacteriologic response to oral cephalosporins: Are established susceptibility breakpoints appropriate in the case of acute otitis media?
113. Pneumococcal macrolide resistance: Myth or reality?
114. Decreased susceptibility of Streptococcua pneumoniae to fluoroquinolones in Canada
115. Emergence of fluoroquinolone resistance among multiply resistant strains of Streptococcus pneumoniae in Hong Kong
116. Streptococcus pneumoniae resistance to fluoroquinolones
117. Increased incidence of ciprofloxacin resistance in penicillin-resistant pneumococci in Northern Ireland
118. Activities of RPR 106972 (a new oral streptogranrin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci
119. Comparative activities of LY 333328, a new glycopeptide, against penicillin-susceptible and -resistant pneumococci
120. Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain
121. Bacteremia with Streptococcus pneumoniae: Implications for therapy and prevention. Franklin County Pneumonia Study Group
122. Mortality from invasive pneumococcal pneumonia in an era of antibiotic resistance. 1995-1997
123. Triple threat of aspiration pneumonia
124. Acid aspiration induced lung injury: New insights and therapeutic options
125. Anaerobic bacterial infections of the lung and pleural space
126. Bacteriologic diagnosis in anaerobic pleuropulmonary infections
127. Quantitative culture of bronchoalveolar lavage from patients with anaerobic lung abscesses
128. Anaerobic bacterial pneumonitis
129. Clindamycin compared with penicillin for the treatment of anaerobic lung abscess
130. Clindamycin vs. penicillin for anaerobic lung infections: High rate of penicillin failures associated with penicillin-resistant Bacteroides melaninogenicus
131. Monotherapy using amoxicillin/clavulanic acid as treatment of first choice in community-acquired lung abscess: Apropos of 57 cases
132. Chlamydia pneumoniae (TWAR)
133. Pneumonia due to Chlamydia pneumoniae: Prevalence, clinical features, diagnosis, and treatment
134. Diagnostic methods for intracellular pathogens
135. Prevalence of asymptomatic nasopharyngeal carriage of Chlamydia pneumoniae in subjectively healthy adults: Assessment by polymerase chain reaction - Enzyme immunoassay and culture
136. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae
137. Legionellosis
138. Case definitions for infectious conditions under public health surveillance
139. Antimicrobial chemotherapy for legionnaires' disease: A review
140. Antimicrobial therapy for legionnaires' disease: Time for a change
141. Delay in appropriate therapy of legionella pneumonia associated with increased mortality
142. Hantavirus: A global disease problem
143. Long-term studies of hantavirus reservoir populations in the Southwestern United States: Rationale, potential and methods
144. An outbreak of hantavirus pulmonary syndrome, Chile, 1997
145. Update: Hantavirus pulmonary syndrome - United States, 1999
146. Hantavirus pulmonary syndrome: The first 100 US cases
147. Mycoplasma pneumoniae pneumonia in an urban area
148. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia
149. Rapid noninvasive diagnosis of Pneumocystis carinii from induced liquefied sputum
150. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS
151. Prevention and control of influenza
152. Asian influenza A in Boston, 1957-58
153. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults
154. Treating influenza with zanamivir
155. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections
156. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B infections
157. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza
158. The efficacy of influenza vaccine in elderly persons: A meta-analysis and review of the literature
159. Influenza vaccination of health care workers in long-term care hospitals reduces the mortality of elderly patients
160. Effectiveness of influenza vaccine in health care professionals
161. Pleural fluid chemical analysis in parapneumonic effusions: A meta-analysis
162. Bacteremic and nonbacteremic pneumococcal pneumonia: A prospective study
163. Parapneumonic effusions
164. Empyema
165. Management of complicated parapneumonic effusions
166. National trends in the use of antibiotics by primary care physicians for adult patients with cough
167. Cough illness/bronchitis: Principles of judicious use of antimicrobial agents
168. Preventing the emergence of antibiotic resistance
169. Rhinovirus infections in an industrial population II. Characteristics of illness and antibody response
170. Does this patient have community-acquired pneumonia?
171. Acute bronchitis
172. Airway infection
173. Role of the microbiology laboratory in the diagnosis of lower respiratory tract infections
174. Acute bacterial exacerbations in bronchitis and asthma
175. Role of infection in chronic bronchitis
176. Treatment of acute bronchitis in adults without underlying lung disease
177. Acute bronchitis
178. Randomized, placebo-controlled trials of antibiotics for acute bronchitis: A critical review of the literature
179. Antibiotics and respiratory infections: Are patients more satisfied when expectations are met?
180. Antibiotics in acute bronchitis: A meta-analysis
181. Prevalence and incidence of adult pertussis in an urban population
182. The looming threat of bioterrorism
183. Anthrax: Civilian medical and public health management following use of a biological weapon
184. Plague as a biological weapon: Medical and public health management. Working Group on Civilian Biodefense
185. Quality of care, process and outcomes in elderly patients with pneumonia
186. Associations between initial antimicrobial regimens and medical outcomes for elderly patients with pneumonia
187. Treatment outcomes associated with community-acquired pneumonia (CAP) in US hospitals: A 3000 patient survey
188. Failure of treatment of pneumonia associated with highly resistant pneumococcus in a child
189. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides
190. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of Haemophilus influenzae and Streptococcus pneumoniae
191. Medical outcomes and antimicrobial costs with the use of the American Thoracic Society guidelines for outpatients with community-acquired pneumonia
192. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: A prospective, randomized multicenter trial
193. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia
194. Once-daily sparfloxacin versus high-dosage amoxicillin in the treatment of community-acquired, suspected pneumococcal pneumonia in adults
195. Penetration of antibiotics into respiratory secretions
196. Endobronchial pH: Relevance to aminoglycoside activity in gram-negative bacillary pneumonia
197. Tetracyclines, chloramphenicol, erythromycin and clindamycin
198. Doxycydine activity against Streptococcus pneumoniae
199. Doxycycline revisited
200. Susceptibility of penicillin-susceptible and resistant pneumococci to dirithromycin compared to susceptibilities to erythromycin, azithromycin, clarithromycin, roxithromycin, and clindamycin
201. Antibiotics for pneumonia therapy
202. Chlamydia pneumoniae, strain TWAR pneumonia
203. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias
204. Sequential antibiotic therapy: Effective cost management and patient care
205. The radiographic resolution of Streptococcus pneumoniae pneumonia
206. Comparative radiographic features of community-acquired legionnaires' disease, pneumococcal pneumonia, Mycoplasma pneumoniae, and psittacosis
207. Prevention of pneumococcal pneumonia by immunization with specific capsular polysaccharides
208. Prevention of pneumococcal pneumonia by vaccination
209. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine
210. Prevention Prevention of pneumococcal disease
211. Pneumococcal polysaccharide vaccine efficacy: An evaluation of current recommendations
212. Efficacy of pneumococcal vaccine in high-risk patients: Results of a Veterans' Administration cooperative study
213. Pneumococcal vaccination: Contro-versies and opportunities
214. Pneumococcal vaccine after 15 years of use: Another view
215. Pneumococcal bacteremia in Charleston County, South Carolina: A decade later